Anteris Advances DurAVR THV With IDE and Trial Readiness
MINNEAPOLIS & BRISBANE, May 13, 2025—Anteris Technologies Global Corp. announced its first-quarter 2025 results, revealing significant progress across clinical...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MINNEAPOLIS & BRISBANE, May 13, 2025—Anteris Technologies Global Corp. announced its first-quarter 2025 results, revealing significant progress across clinical...
